However, depleting TAMs with CSF1/CSF1R blockers has limited monotherapy efficacy, except in diffuse-type giant cell tumours that overexpress CSF1 [16, 17], because the benefits from TAM depletion are counteracted by enhanced recruitment of granulocytic myeloid-derived suppressor cells (MDSCs) [16]. Here, CSF1 is linked to tenosynovial giant cell tumor, diffuse type.